Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CD69 | Q07108 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31616127 | 0.85 | TTR (0.48) | PTGDR2TTRALBHPGDTHRA | |
| SCHEMBL14040248 | 0.80 | THRA (0.46) | THRATHRBALOX15KMT2ACD69 | |
| SCHEMBL5533531 | 0.79 | HPGD (0.48) | PTGDR2TTRALBHPGDTHRA | |
| SCHEMBL10495696 | 0.79 | HPGD (0.42) | PTGDR2HPGDTHRATHRBALOX15 | |
| SCHEMBL22359890 | 0.77 | THRA (0.50) | PTGDR2HPGDTHRATHRBKMT2A | |
| SCHEMBL31453936 | 0.77 | ALOX15 (0.53) | PTGDR2HPGDALOX15KMT2AFFAR1 | |
| SCHEMBL6724871 | 0.77 | THRA (0.57) | THRATHRBALOX15KMT2ACD69 | |
| SCHEMBL6720881 | 0.75 | THRB (0.49) | TTRTHRATHRBALOX15KMT2A | |
| SCHEMBL5276461 | 0.72 | TSHR (0.49) | PTGDR2THRATHRBCD69ELANE | |
| SCHEMBL8413020 | 0.71 | KMT2A (0.42) | HPGDTHRATHRBALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2388003-B1 | Colchicine derivatives | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3207929-B1 | COLCHICINE DERIVATIVES FOR THE TREATMENT OF CANCER | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3207929-A2 | COLCHICINE DERIVATIVES | California Pacific Medical Center (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-1617843-B1 | COLCHICINE DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-1643987-B1 | PODOPHYLLOTOXIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2016-11-30 | — | — | EP | disclosed |
| US-8158809-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2388003-A2 | Colchicine derivatives | California Pacific Medical Center (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | Sutter West Bay Hospitals, dba California Pacific Medical Center and Catholic Healthcare West | 2009-12-03 | — | — | US | disclosed |
| US-7605262-B2 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1643987-A4 | PODOPHYLLOTOXIN DERIVATIVES | CALIFORNIA PACIFIC MED CENTER (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2005007076-A2 | COLCHICINE DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050004169-A1 | Podophyllotoxin derivatives | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2005-01-06 | — | — | US | disclosed |
| CN-1553802-A | Camptothecin derivatives | ����������̫ƽ��ҽѧ���� | 2004-12-08 | — | — | CN | disclosed |
| US-6825236-B2 | ACTIVE AGAINST TUMORS IN MICE AND ARE GENERALLY WELL TOLERATED | CALIFORNIA PACIFIC MEDICAL CENTER | 2004-11-30 | — | — | US | disclosed |
| US-20040204370-A1 | COLCHICINE DERIVATIVES | SUTTER WEST BAY HOSPITALS, DBA CALIFORNIA PACIFIC MEDICAL CENTER | 2004-10-14 | — | — | US | disclosed |
| US-20040034050-A1 | Homo-camptothecin derivatives | CATHOLIC HEALTHCARE WEST, DOING BUSINESS AS ST. MARY'S MEDICAL CENTER OF SAN FRANCISCO | 2004-02-19 | — | — | US | disclosed |
| WO-2003101406-A1 | HOMO-CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-1353673-A1 | CAMPTOTHECIN DERIVATIVES | California Pacific Medical Center (US) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002056885-A1 | CAMPTOTHECIN DERIVATIVES | CALIFORNIA PACIFIC MEDICAL CENTER (US) | 2002-07-25 | — | — | WO | disclosed |
| US-6350756-B1 | USEFUL FOR TREATING CANCER; (20S) ESTERS WITH AN OXYALKANOIC ACID; | CALIFORNIA PACIFIC MEDICAL CENTER | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004169-A1 | Podophyllotoxin derivatives | APEH, DAGLA, DPY30 | PTGDR2 1000/4885TTR 2527/4885ALB 3983/4885 |
| US-20040204370-A1 | COLCHICINE DERIVATIVES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, NAP1L4 | PTGDR2 4832/4885TTR 2966/4885ALB 2458/4885 |
| US-20040034050-A1 | Homo-camptothecin derivatives | CYP8B1, HCAR3, MTHFD2 | PTGDR2 630/4885TTR 2593/4885ALB 4573/4885 |
| US-20090298870-A1 | PODOPHYLLOTOXIN DERIVATIVES | APEH, DAGLA, DPY30 | PTGDR2 1000/4885TTR 2527/4885ALB 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.